OGN - Organon Samsung Bioepis Humira biosimilar Hadlima high concentration dosage gets FDA nod
- The U.S. Food and Drug Administration (FDA) approved a citrate-free, high-concentration (100 mg/mL) formulation of Samsung Bioepis and Organon's ( NYSE: OGN ) Hadlima, a biosimilar to AbbVie's ( ABBV ) blockbuster arthritis/psoriasis therapy Humira (adalimumab).
- The companies said Hadlima (adalimumab-bwwd) will be available in pre-filled syringe and autoinjector options.
- Hadlima was previously approved by the FDA as a low-concentration (50 mg/mL) formulation in July 2019, the companies noted in an Aug. 17 press release.
- Organon expects to launch Hadlima in the U.S. on or after July 1, in 2023.
- Novartis' too has a Humira biosimilar Hyrimoz, whose high concentration formulation of 100 mg/mL is under review by the FDA.
For further details see:
Organon, Samsung Bioepis Humira biosimilar Hadlima high concentration dosage gets FDA nod